Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31


The development and characterization of a chemical probe targeting PRMT1 over PRMT5.

Mann SA, Salsburg A, Causey CP, Knuckley B.

Bioorg Med Chem. 2019 Jan 1;27(1):224-229. doi: 10.1016/j.bmc.2018.12.001. Epub 2018 Dec 4.


Expanding the molecular-ruler process through vapor deposition of hexadecanethiol.

Patron AM, Hooker TS, Santavicca DF, Causey CP, Mullen TJ.

Beilstein J Nanotechnol. 2017 Nov 7;8:2339-2344. doi: 10.3762/bjnano.8.233. eCollection 2017.


Molecular targeting of protein arginine deiminases to suppress colitis and prevent colon cancer.

Witalison EE, Cui X, Causey CP, Thompson PR, Hofseth LJ.

Oncotarget. 2015 Nov 3;6(34):36053-62. doi: 10.18632/oncotarget.5937.


Synthesis and evaluation of 2-ethynyl-adenosine-5'-triphosphate as a chemical reporter for protein AMPylation.

Creech C, Kanaujia M, Causey CP.

Org Biomol Chem. 2015 Aug 21;13(31):8550-5. doi: 10.1039/c5ob01081k.


A novel role for peptidylarginine deiminases in microvesicle release reveals therapeutic potential of PAD inhibition in sensitizing prostate cancer cells to chemotherapy.

Kholia S, Jorfi S, Thompson PR, Causey CP, Nicholas AP, Inal JM, Lange S.

J Extracell Vesicles. 2015 Jun 19;4:26192. doi: 10.3402/jev.v4.26192. eCollection 2015.


Development of a clickable activity-based protein profiling (ABPP) probe for agmatine deiminases.

Marchenko M, Thomson A, Ellis TN, Knuckley B, Causey CP.

Bioorg Med Chem. 2015 May 1;23(9):2159-67. doi: 10.1016/j.bmc.2015.03.013. Epub 2015 Mar 9.


Inhibiting protein arginine deiminases has antioxidant consequences.

Witalison EE, Cui X, Hofseth AB, Subramanian V, Causey CP, Thompson PR, Hofseth LJ.

J Pharmacol Exp Ther. 2015 Apr;353(1):64-70. doi: 10.1124/jpet.115.222745. Epub 2015 Jan 29.


1-Adamantanethiol as a versatile nanografting tool.

Drexler CI, Causey CP, Mullen TJ.

Scanning. 2015 Jan-Feb;37(1):6-16. doi: 10.1002/sca.21173. Epub 2014 Nov 5.


Design, synthesis, and in vitro evaluation of an activity-based protein profiling (ABPP) probe targeting agmatine deiminases.

Thomson A, O'Connor S, Knuckley B, Causey CP.

Bioorg Med Chem. 2014 Sep 1;22(17):4602-8. doi: 10.1016/j.bmc.2014.07.028. Epub 2014 Jul 25.


Atomic force microscopy characterization and lithography of Cu-ligated mercaptoalkanoic acid "molecular ruler" multilayers.

Drexler CI, Moore KB 3rd, Causey CP, Mullen TJ.

Langmuir. 2014 Jul 1;30(25):7447-55. doi: 10.1021/la501645w. Epub 2014 Jun 17.


Identification of PADI2 as a potential breast cancer biomarker and therapeutic target.

McElwee JL, Mohanan S, Griffith OL, Breuer HC, Anguish LJ, Cherrington BD, Palmer AM, Howe LR, Subramanian V, Causey CP, Thompson PR, Gray JW, Coonrod SA.

BMC Cancer. 2012 Oct 30;12:500. doi: 10.1186/1471-2407-12-500.


Potential role for PADI-mediated histone citrullination in preimplantation development.

Kan R, Jin M, Subramanian V, Causey CP, Thompson PR, Coonrod SA.

BMC Dev Biol. 2012 Jun 19;12:19. doi: 10.1186/1471-213X-12-19.


Citrullination of proteins: a common post-translational modification pathway induced by different nanoparticles in vitro and in vivo.

Mohamed BM, Verma NK, Davies AM, McGowan A, Crosbie-Staunton K, Prina-Mello A, Kelleher D, Botting CH, Causey CP, Thompson PR, Pruijn GJ, Kisin ER, Tkach AV, Shvedova AA, Volkov Y.

Nanomedicine (Lond). 2012 Aug;7(8):1181-95. doi: 10.2217/nnm.11.177. Epub 2012 May 25.


Synthesis and screening of a haloacetamidine containing library to identify PAD4 selective inhibitors.

Jones JE, Slack JL, Fang P, Zhang X, Subramanian V, Causey CP, Coonrod SA, Guo M, Thompson PR.

ACS Chem Biol. 2012 Jan 20;7(1):160-5. doi: 10.1021/cb200258q. Epub 2011 Oct 21.


The development of N-α-(2-carboxyl)benzoyl-N(5)-(2-fluoro-1-iminoethyl)-l-ornithine amide (o-F-amidine) and N-α-(2-carboxyl)benzoyl-N(5)-(2-chloro-1-iminoethyl)-l-ornithine amide (o-Cl-amidine) as second generation protein arginine deiminase (PAD) inhibitors.

Causey CP, Jones JE, Slack JL, Kamei D, Jones LE, Subramanian V, Knuckley B, Ebrahimi P, Chumanevich AA, Luo Y, Hashimoto H, Sato M, Hofseth LJ, Thompson PR.

J Med Chem. 2011 Oct 13;54(19):6919-35. doi: 10.1021/jm2008985. Epub 2011 Sep 16. Erratum in: J Med Chem. 2011 Nov 24;54(22):7942.


Activity-based protein profiling of protein arginine methyltransferase 1.

Obianyo O, Causey CP, Jones JE, Thompson PR.

ACS Chem Biol. 2011 Oct 21;6(10):1127-35. doi: 10.1021/cb2001473. Epub 2011 Aug 23.


Genome-wide analysis reveals PADI4 cooperates with Elk-1 to activate c-Fos expression in breast cancer cells.

Zhang X, Gamble MJ, Stadler S, Cherrington BD, Causey CP, Thompson PR, Roberson MS, Kraus WL, Coonrod SA.

PLoS Genet. 2011 Jun;7(6):e1002112. doi: 10.1371/journal.pgen.1002112. Epub 2011 Jun 2.


Protein deiminases: new players in the developmentally regulated loss of neural regenerative ability.

Lange S, Gögel S, Leung KY, Vernay B, Nicholas AP, Causey CP, Thompson PR, Greene ND, Ferretti P.

Dev Biol. 2011 Jul 15;355(2):205-14. doi: 10.1016/j.ydbio.2011.04.015. Epub 2011 Apr 22.


Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor.

Chumanevich AA, Causey CP, Knuckley BA, Jones JE, Poudyal D, Chumanevich AP, Davis T, Matesic LE, Thompson PR, Hofseth LJ.

Am J Physiol Gastrointest Liver Physiol. 2011 Jun;300(6):G929-38. doi: 10.1152/ajpgi.00435.2010. Epub 2011 Mar 17.


N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis.

Willis VC, Gizinski AM, Banda NK, Causey CP, Knuckley B, Cordova KN, Luo Y, Levitt B, Glogowska M, Chandra P, Kulik L, Robinson WH, Arend WP, Thompson PR, Holers VM.

J Immunol. 2011 Apr 1;186(7):4396-404. doi: 10.4049/jimmunol.1001620. Epub 2011 Feb 23.


Development and use of clickable activity based protein profiling agents for protein arginine deiminase 4.

Slack JL, Causey CP, Luo Y, Thompson PR.

ACS Chem Biol. 2011 May 20;6(5):466-76. doi: 10.1021/cb1003515. Epub 2011 Feb 7.


Mechanistic studies of agmatine deiminase from multiple bacterial species.

Jones JE, Dreyton CJ, Flick H, Causey CP, Thompson PR.

Biochemistry. 2010 Nov 2;49(43):9413-23. doi: 10.1021/bi101405y.


A fluopol-ABPP HTS assay to identify PAD inhibitors.

Knuckley B, Jones JE, Bachovchin DA, Slack J, Causey CP, Brown SJ, Rosen H, Cravatt BF, Thompson PR.

Chem Commun (Camb). 2010 Oct 14;46(38):7175-7. doi: 10.1039/c0cc02634d. Epub 2010 Aug 25.


Protein arginine deiminase 4: a target for an epigenetic cancer therapy.

Slack JL, Causey CP, Thompson PR.

Cell Mol Life Sci. 2011 Feb;68(4):709-20. doi: 10.1007/s00018-010-0480-x. Epub 2010 Aug 13.


A chloroacetamidine-based inactivator of protein arginine methyltransferase 1: design, synthesis, and in vitro and in vivo evaluation.

Obianyo O, Causey CP, Osborne TC, Jones JE, Lee YH, Stallcup MR, Thompson PR.

Chembiochem. 2010 Jun 14;11(9):1219-23. doi: 10.1002/cbic.201000209. No abstract available.


Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3.

Knuckley B, Causey CP, Jones JE, Bhatia M, Dreyton CJ, Osborne TC, Takahara H, Thompson PR.

Biochemistry. 2010 Jun 15;49(23):4852-63. doi: 10.1021/bi100363t.


Characterization and inactivation of an agmatine deiminase from Helicobacter pylori.

Jones JE, Causey CP, Lovelace L, Knuckley B, Flick H, Lebioda L, Thompson PR.

Bioorg Chem. 2010 Apr;38(2):62-73. doi: 10.1016/j.bioorg.2009.11.004. Epub 2009 Nov 29.


Haloacetamidine-based inactivators of protein arginine deiminase 4 (PAD4): evidence that general acid catalysis promotes efficient inactivation.

Knuckley B, Causey CP, Pellechia PJ, Cook PF, Thompson PR.

Chembiochem. 2010 Jan 25;11(2):161-5. doi: 10.1002/cbic.200900698.


Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential.

Jones JE, Causey CP, Knuckley B, Slack-Noyes JL, Thompson PR.

Curr Opin Drug Discov Devel. 2009 Sep;12(5):616-27. Review.


Anion binding by fluorescent biimidazole diamides.

Causey CP, Allen WE.

J Org Chem. 2002 Aug 23;67(17):5963-8.


Supplemental Content

Loading ...
Support Center